The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
 
Philippos Costa
Stock and Other Ownership Interests - SpringWorks Therapeutics
 
Mary Josephine Pilat
No Relationships to Disclose
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Melissa Burgess
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie
Research Funding - Merck
 
Gabriel Tinoco
Consulting or Advisory Role - Deciphera; Deciphera; Deciphera; Deciphera; SynOX
 
Julia Close
No Relationships to Disclose
 
Roman Groisberg
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Vivek Subbiah
Consulting or Advisory Role - AADi; Abbvie (Inst); Bayer (Inst); Foundation Medicine; Illumina; Incyte (Inst); Loxo/Lilly; Novartis (Inst); Pfizer (Inst); Pheon Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst)
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Relay Therapeutics (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Other Relationship - Clinical Care Options; Medscape
 
Benjamin Powers
No Relationships to Disclose
 
Candace Haddox
Employment - Dana-Farber Cancer Institute
Honoraria - Horizon CME; i3 Health
Consulting or Advisory Role - AADi; deciphera; SpringWorks Therapeutics
Research Funding - AADi (Inst); ASCO; Cogent Biosciences (Inst); EMD Serono/Merck (Inst); HiFiBiO Therapeutics (Inst); Roche/Genentech (Inst); Tango Therapeutics (Inst); Tubulis GmbH (Inst)
 
Juneko Grilley-Olson
Consulting or Advisory Role - Deciphera; Ipsen
Research Funding - InhibRx (Inst); Polaris (Inst); PTC Therapeutics (Inst)
 
Vicki Keedy
Employment - Johnson & Johnson/Janssen (I)
Consulting or Advisory Role - Deciphera
Research Funding - Adaptimmune (Inst); Advenchen Laboratories (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); Shanghai Pharma (Inst); Tizona Therapeutics, Inc. (Inst); TRACON Pharma (Inst)
 
Jing Li
No Relationships to Disclose
 
S. Ivy
No Relationships to Disclose
 
Abhijit Patel
Employment - Binary Genomics
Leadership - Binary Genomics
Stock and Other Ownership Interests - Binary Genomics
Honoraria - NuGEN
Consulting or Advisory Role - Binary Genomics; NuProbe
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Inventor and assignee of patents and patent applications covering ultra sensitive nucleic acid analysis technologies.
Travel, Accommodations, Expenses - Binary Genomics
 
Geoffrey Shapiro
Consulting or Advisory Role - Bicycle Therapeutics; Merck Serono; Xinthera
Research Funding - Bristol-Myers Squibb/Medarex (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Pfizer (Inst); Tango Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Patent # 10,934,593 B2 Compositions and methods for predicting response and resistance to CDK4/6 inhibition; Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018
 
Jeffrey Ishizuka
Stock and Other Ownership Interests - Curios Therapeutics; Jounce Therapeutics; Kronos Bio
Consulting or Advisory Role - Danger Bio; Fortress Biotech; Ono Pharmaceutical; Phenomic AI; Rheos Medicines; Tango Therapeutics; Two River Group
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - I am an inventor on a patent on approaches targeting dsRNA sensing titled: "MODULATING dsRNA EDITING, SENSING, AND METABOLISM TO INCREASE TUMOR IMMUNITY AND IMPROVE THE EFFICACY OF CANCER IMMUNOTHERAPY AND/OR MODULATORS OF INTRATUMORAL INTERFERON".
 
Kurt Schalper
Consulting or Advisory Role - Abbvie; Agenus; AstraZeneca; Bristol Myers Squibb; CDR-Life; Clinica Alemana; DynamiCure Biotechnology; Indaptus; Janssen; Menarini; Merus; Molecular Templates; OnCusp Therapeutics; Parthenon Therapeutics; Picture Health; Roche; Sanofi; Takeda
Speakers' Bureau - Forefront Collaborative; HMP; Merck; Peerview; PeerView; Sanofi
Research Funding - Akoya Biosciences (Inst); AstraZeneca; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Lilly; Merck; Ribon Therapeutics; Roche (Inst); Takeda; Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Patent No. 16/464,010 (PREDICTION OF RESPONSE TO IMMUNE-MODULATORY THERAPIES)
Expert Testimony - AstraZeneca
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Actuate Therapeutics; Agenus; Amgen; AstraZeneca; Atreca; BAKX Therapeutics; Boehringer Ingelheim; Compass Therapeutics; Cullinan Oncology; DAAN Biotherapeutics; EMD Serono; GlaxoSmithKline; I-Mab; ImCheck therapeutics; IQvia; Kineta; Kyowa Kirin International; Mekanistic Therapeutics; Mersana; Molecular Templates; Neurotrials Research; Pfizer; QED Therapeutics; Qualigen Therapeutics; Quanta Therapeutics; Relay Therapeutics; Roche/Genentech; Roivant; Scenic Biotech; Schrodinger; Seagen; Sotio; ST Cube; Stemline Therapeutics; Takeda; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech